Dr. Deepti Behl
Claim this profileCalifornia Pacific Medical Center-Pacific Campus
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
50 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
Stage I
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Deepti Behl is currently running
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria
Targeted Therapy
for Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
More about Deepti Behl
Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Deepti Behl has experience with
- Pembrolizumab
- Carboplatin
- Atezolizumab
- Placebo
- Durvalumab
- Olaparib
Breakdown of trials Deepti Behl has run
Lung Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Fallopian Tube Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Deepti Behl specialize in?
Deepti Behl focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Deepti Behl currently recruiting for clinical trials?
Yes, Deepti Behl is currently recruiting for 2 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Deepti Behl has studied deeply?
Yes, Deepti Behl has studied treatments such as Pembrolizumab, Carboplatin, Atezolizumab.
What is the best way to schedule an appointment with Deepti Behl?
Apply for one of the trials that Deepti Behl is conducting.
What is the office address of Deepti Behl?
The office of Deepti Behl is located at: California Pacific Medical Center-Pacific Campus, San Francisco, California 94115 United States. This is the address for their practice at the California Pacific Medical Center-Pacific Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.